Annovis Bio, Inc. (NYSE:ANVS) CEO Maria-Luisa Maccecchini bought 18,000 shares of the business’s stock in a transaction that occurred on Monday, October 11th. The stock was purchased at an average price of $27.61 per share, with a total value of $496,980.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.
Shares of ANVS stock traded up $0.37 on Wednesday, hitting $27.50. The company’s stock had a trading volume of 96,706 shares, compared to its average volume of 732,821. Annovis Bio, Inc. has a fifty-two week low of $4.14 and a fifty-two week high of $132.00. The stock’s 50 day moving average is $34.81 and its 200-day moving average is $50.00. The company has a market capitalization of $222.78 million, a PE ratio of -24.63 and a beta of 2.17.
Annovis Bio (NYSE:ANVS) last posted its quarterly earnings data on Tuesday, July 27th. The company reported ($0.34) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.37) by $0.03.
Institutional investors have recently bought and sold shares of the company. US Bancorp DE bought a new position in shares of Annovis Bio in the second quarter worth about $43,000. Wells Fargo & Company MN lifted its stake in shares of Annovis Bio by 2,048.0% in the 2nd quarter. Wells Fargo & Company MN now owns 537 shares of the company’s stock valued at $47,000 after acquiring an additional 512 shares during the last quarter. Bridgeway Capital Management LLC boosted its holdings in shares of Annovis Bio by 4.9% during the 2nd quarter. Bridgeway Capital Management LLC now owns 23,600 shares of the company’s stock valued at $2,020,000 after acquiring an additional 1,100 shares in the last quarter. Northern Trust Corp boosted its stake in shares of Annovis Bio by 22.5% during the second quarter. Northern Trust Corp now owns 9,098 shares of the company’s stock valued at $779,000 after purchasing an additional 1,673 shares in the last quarter. Finally, National Asset Management Inc. bought a new stake in shares of Annovis Bio during the second quarter worth about $208,000. 15.60% of the stock is owned by institutional investors.
About Annovis Bio
Annovis Bio, Inc, a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead compound is ANVS401, which is in Phase 2a clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, Alzheimer's disease in Down Syndrome, and other chronic neurodegenerative disorders.
Featured Article: What is the Dividend Aristocrat Index?
Receive News & Ratings for Annovis Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Annovis Bio and related companies with MarketBeat.com's FREE daily email newsletter.